

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MedSci Healthcare Holdings Limited

梅斯健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2415)

INSIDE INFORMATION POSITIVE PROFIT ALERT

This announcement is made by MedSci Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2025 and an assessment of the information currently available to the Board, the Group is expected to record a profit attributable to the Shareholders of not less than RMB10 million for the six months ended 30 June 2025 as compared to a profit attributable to the Shareholders of RMB0.2 million recorded for the six months ended 30 June 2024. The expected increase in profit of the Group was mainly attributable to the following: (i) the resurgence of the pharmaceutical industry and the accelerated transformation of evidence-driven marketing tools in domestic pharmaceutical companies driving the growing demand for precision omni-channel marketing solutions; (ii) the use of artificial intelligence empowering production efficiency of various business segments of the Group; and (iii) the proactive implementation of the principals of environmental, social and governance, resulting in better control of operating costs.

As the Company is still in the process of preparing and finalising the interim results of the Group for the six months ended 30 June 2025, information contained in this announcement is only based on a preliminary assessment by the Company's management team with reference to the unaudited consolidated management accounts of the Group for the six months ended 30 June 2025 and information currently available to the Company, which has not been audited or reviewed by the Company's auditor or the audit committee of the Company and may therefore be subject to changes. Shareholders and potential investors should read the Company's interim results announcement for the six months ended 30 June 2025 carefully, which is expected to be published in August 2025.

By order of the Board
MedSci Healthcare Holdings Limited
梅斯健康控股有限公司

Dr. Zhang Fabao
Chairman of the Board and Executive Director

Hong Kong, 20 August 2025

As at the date of this announcement, the Board comprises Dr. Zhang Fabao, Dr. Li Xinmei, Mr. Wang Shuai and Mr. Cheng Liang as executive Directors; Ms. Wang Xin and Mr. Yan Shengfeng, as non-executive Directors; and Ms. Liu Tao, Mr. Yu Mingyang and Mr. Lau Yiu Kwan Stanley, as independent non-executive Directors.